UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for lung cancer (NSCLC and SCLC) in the United Kingdom. Explore treatment pathways based on biomarkers and stage.
Lung cancer is the third most common cancer in the UK with ~48,000 new cases yearly. There are two main types: non-small cell lung cancer (NSCLC, ~85%) and small cell lung cancer (SCLC, ~15%). Treatment has been revolutionised by biomarker testing - identifying specific genetic mutations (EGFR, ALK, ROS1, KRAS) and PD-L1 levels guides personalised treatment.
Every lung cancer patient should have biomarker testing. Key biomarkers: EGFR mutations (~15% of NSCLC, treated with osimertinib), ALK rearrangements (~5%, treated with alectinib), ROS1 (~2%, treated with entrectinib), KRAS G12C (~13%, treated with sotorasib), and PD-L1 expression (guides immunotherapy with pembrolizumab). Testing is done on biopsy tissue using next-generation sequencing (NGS).
Early stage NSCLC: surgery ± adjuvant immunotherapy. Advanced NSCLC: first-line treatment depends on biomarkers - targeted therapy for mutations, immunotherapy ± chemo for PD-L1 positive. SCLC: chemotherapy + immunotherapy (atezolizumab or durvalumab). Second-line options include docetaxel, lorlatinib (ALK), and clinical trials.
Lung cancer has more clinical trials than almost any other cancer. Current areas of research include: next-generation targeted therapies for KRAS and other mutations, new immunotherapy combinations, antibody-drug conjugates, and cancer vaccines. The UK is a major hub for lung cancer research with the NHS providing trial access nationwide.
Free AI-powered matching - no signup required
Search non-small cell lung cancer Trials →